Mazen Hanna
- Nephrology top 0.2%
- Parathyroid Disorders and Treatments 41
-
- Cardiovascular Function and Risk Factors 14
- Cardiomyopathy and Myosin Studies 10
- Molecular Biology top 2%
- Amyloidosis: Diagnosis, Treatment, Outcomes 101
- Rheumatology top 1%
- Eosinophilic Disorders and Syndromes 19
-
- Peptidase Inhibition and Analysis 22
-
- Coagulation, Bradykinin, Polyphosphates, and Angioedema 16
-
- Sarcoidosis and Beryllium Toxicity Research 12
- Co-authors
- Martha GroganMathew S. MaurerFrederick L. RubergJeffery W. KellyDermot PhelanBrett W. SperryJoseph P. DonnellyWael A. Jaber
- Journals
- Circulation (3 papers)SHILAP Revista de lepidopterología (4 papers)Journal of the American College of Cardiology (14 papers)
- Partner nations
- United StatesUnited KingdomItaly
In The Last Decade
Mazen Hanna
121 papers receiving 4.7k citations
Hit Papers
Peers
Comparison fields: 5 of 104
- Nephrology 1.4k
- Physical and Theoretical Chemistry 541
- Cardiology and Cardiovascular Medicine 1.3k
- Molecular Biology 3.3k
- Rheumatology 669
Countries citing papers authored by Mazen Hanna
This map shows the geographic impact of Mazen Hanna's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mazen Hanna with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mazen Hanna more than expected).
Fields of papers citing papers by Mazen Hanna
This network shows the impact of papers produced by Mazen Hanna. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mazen Hanna. The network helps show where Mazen Hanna may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Mazen Hanna, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 7 | |
| 2 | 2025 | 1 | |
| 3 | 2025 | 0 | |
| 4 | 2025 | 0 | |
| 5 | 2024 | 2 | |
| 6 | 2024 | 4 | |
| 7 | 2024 | 1 | |
| 8 | 2023 | 1 | |
| 9 | 2023 | 15 | |
| 10 | 2023 | 4 | |
| 11 | 2023 | 3 | |
| 12 | 2023 | 2 | |
| 13 | 2023 | 1 | |
| 14 | 2022 | 8 | |
| 15 | 2022 | 0 | |
| 16 | 2020 | 34 | |
| 17 | Abstract 14214: ATTRibute-CM: A Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Global Phase 3 Study of AG10 in Patients With Transthyretin Amyloid Cardiomyopathy (ATTR-CM) | 2019 | 5 |
| 18 | 2019 | 180 | |
| 19 | 2018 | 50 | |
| 20 | 2017 | 17 |
About Mazen Hanna
Mazen Hanna is a scholar working on Nephrology, Cardiology and Cardiovascular Medicine and Molecular Biology, having authored 133 papers that have together received 4.8k indexed citations. Recurring topics across this work include Amyloidosis: Diagnosis, Treatment, Outcomes (101 papers), Parathyroid Disorders and Treatments (41 papers), Peptidase Inhibition and Analysis (22 papers), Eosinophilic Disorders and Syndromes (19 papers), Coagulation, Bradykinin, Polyphosphates, and Angioedema (16 papers), Cardiovascular Function and Risk Factors (14 papers), Sarcoidosis and Beryllium Toxicity Research (12 papers) and Cardiomyopathy and Myosin Studies (10 papers). The work is most often cited by research in Nephrology (1.4k citations), Physical and Theoretical Chemistry (541 citations) and Cardiology and Cardiovascular Medicine (1.3k citations). Mazen Hanna has collaborated with scholars based in United States, United Kingdom and Italy. Frequent co-authors include Martha Grogan, Mathew S. Maurer, Frederick L. Ruberg, Jeffery W. Kelly, Dermot Phelan, Brett W. Sperry, Joseph P. Donnelly, Wael A. Jaber, Ning Shan and Michael J. Zaworotko. Their work appears in journals such as Circulation, SHILAP Revista de lepidopterología and Journal of the American College of Cardiology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.